AIM ImmunoTech Inc. (AIM) Form 10-Q — Aug 7, 2026
AIM ImmunoTech reported a Q2 2026 net loss of $3.8 million, up 35.6% from $2.8 million a year earlier, on de minimis revenue of $26 thousand from US clinical treatment programs, with the wider loss driven mainly by offering-related costs as general and administrative expense nearly doubled to $2.9 million. The company disclosed substantial doubt about its ability to continue as a going concern while massively diluting shareholders: shares outstanding grew roughly nine-fold from 3.1 million to 29.0 million during H1 2026 through a rights offering, two registered direct offerings, a warrant inducement priced at $0.48, and ATM sales, leaving about 48.5 million options and warrants outstanding.
Key figures
- Revenue
- 26000
- Total Debt
- 3621000
- Revenue Yoy
- 4.0% (Q2 2026: $26K vs $25K in Q2 2025)
- Total Assets
- 12731000
- Cash Position
- 9900000
- Shares Outstanding
- 30,442,139 as of Aug 7, 2026; 28,990,073 as of Jun 30, 2026 (vs 3,069,875 at Dec 31, 2025)
- Q2 r and d
- 589000
- Q2 ga expense
- 2945000
- Q2 r and d yoy
- -49.8%
- Q2 ga expense yoy
- 98.0% increase
- Q2 interest expense
- 295000
- Reverse split ratio
- 1:100 (effected June 10, 2025)
- Six month revenue 2025
- 41000
- Six month revenue 2026
- 48000
- Nyse equity requirement
- $6.0 million (satisfied June 10, 2026)
- Atm gross proceeds h1 2026
- 2600000
- Net financing cash h1 2026
- 14373000
- Share count growth h1 2026
- ~844% increase (3,069,875 to 28,990,073)
- Rights offering gross proceeds
- 1800000
- Class i offering gross proceeds
- 2400000
- Class j offering gross proceeds
- 2600000
- Stockholders equity jun 30 2026
- 7744000
- Class h inducement gross proceeds
- 3600000
- Warrant liability reclass to equity
- 8700000
- Class h value transferred to holders
- 6600000
- Streeterville note outstanding balance
- ~$1.7 million (per May 18, 2026 amendment; maturity extended to June 30, 2027)
- Options and warrants outstanding antidilutive
- 48470384
Price after filing
Close on the filing date to close N calendar days later (from $0.27). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.